drugset
drugset / Trial / NCT00651131

Cubicin(R) for Complicated Post-surgical Wound Infections

NCT00651131 ↗

Phase 4 Terminated 69 enrolled Merck & Co., Inc.
RandomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to describe the clinical efficacy of CUBICIN therapy in patients with superficial and deep post-surgical Gram-positive wound infections

Timeline

Start
2004-06-01
Primary completion
2005-03-01
Completion
2005-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Daptomycin Other / unclassified 4 mg/kg Intravenous

Indications

No indication recorded.